News
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Evolva and Nice & Green agree on improvements to financing agreement
Evolva and Nice & Green agree on improvements to financing agreement
Dominik Arnold to become new CEO of the COLTENE Group
Dominik Arnold to become new CEO of the COLTENE Group
Evolva receives approval for Veri-teTM Resveratrol in Thailand
Evolva receives approval for Veri-teTM Resveratrol in Thailand
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023
Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023
Evolva with good business momentum and significant progress in profitability in 1H 2023, despite major financing challenges
Evolva with good business momentum and significant progress in profitability in 1H 2023, despite major financing challenges
Kuros Biosciences Reports Results for First Half 2023
Kuros Biosciences Reports Results for First Half 2023
H1 2023 result outperforms prior year at constant exchange rates
H1 2023 result outperforms prior year at constant exchange rates
Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year
Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year
Evolva receives approval for Veri-teTM Resveratrol in Taiwan
Evolva receives approval for Veri-teTM Resveratrol in Taiwan
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
Evolva Holding SA: Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives
Evolva Holding SA: Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
Sonova further extends offering of Sennheiser-branded hearing solutions with All-Day Clear
Sonova further extends offering of Sennheiser-branded
hearing solutions with All-Day Clear
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Annual General Shareholders’ Meeting 2023: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2023:
Sonova shareholders approve all motions of the Board of Directors